Variant with L130M+V131I mutations may also exert a synergistic effect in accelerating the progression to HCC 92, which was recently reported to promote HCC progression by activating AKT/FOXO1 pathway and inducing more severe inflammation in liver via arachidonic acid metabolism 93. The gene discussed is FOXO1; the disease is hepatocellular carcinoma.